CoChat

An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism

Open access
Nieschlag, Eberhard, Bouloux, Pierre-Marc G., Stegmann, Barbara J., Shankar, R. Ravi, Guan, Yanfen, Tzontcheva, Anjela, McCrary Sisk, Christine, Behre, Hermann M. · 2017 · Reproductive Biology and Endocrinology

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Hypogonadotropic hypogonadism (HH) in men results in insufficient testicular function and deficiencies in testosterone and spermatogenesis. Combinations of human chorionic gonadotropin (hCG) and recombinant follicle-stimulating hormone (recFSH) have been successful in the treatment of HH. Corifollitropin alfa is a long-acting FSH-analog with demonstrated action in women seeking infertility care. The aim of this study was to investigate the efficacy and safety of corifollitropin alfa combined with hCG to increase testicular volume and induce spermatogenesis in men with HH. This was a Phase III, multi-center, open-label, single-arm trial of corifollitropin alfa in azoospermic men aged 18 to 50 years with HH. After 16 weeks of pretreatment of 23 subjects with hCG alone, 18 subjects with normalized testosterone (T) levels who remained azoospermic entered the 52-week combined treatment phase with hCG twice-weekly and 150 μg corifollitropin alfa every other week. The increase in testicular volume (primary efficacy endpoint) and induction of spermatogenesis resulting in a sperm count ≥1 × 106/mL (key secondary efficacy endpoint) during 52 weeks of combined treatment were assessed. Safety was evaluated by the presence of anti-corifollitropin alfa antibodies and the occurrence of adverse events (AEs). Mean (±SD) testicular volume increased from 8.6 (±6.09) mL to 17.8 (±8.93) mL (geometric mean fold increase, 2.30 [95% CI: 2.03, 2.62]); 14 (77.8%) subjects reached a sperm count ≥1 × 106/mL. No subject developed confirmed anti-corifollitropin alfa antibodies during the trial. Treatment was generally well tolerated. Corifollitropin alfa 150 μg administrated every other week combined with twice-weekly hCG for 52 weeks increased testicular volume significantly, and induced spermatogenesis in >75% of men with HH who had remained azoospermic after hCG treatment alone. ClinicalTrials.gov: NCT01709331 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12958-017-0232-y

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mean (±SD) testicular volume at each study visit from pretreatment baseline to Week 52 of the combined treatment phase
Fig. 1 Mean (±SD) testicular volume at each study visit from pretreatment baseline to Week 52 of the combined treatment phaseCC BY · PubMed Central
Fig. 2 a Mean (±SD) sperm concentration (×106) from Day 1 to Week 52 of the combined treatment phase; b Total sperm count (×106/ejaculate) during the combined treatment phase
Fig. 2 a Mean (±SD) sperm concentration (×106) from Day 1 to Week 52 of the combined treatment phase; b Total sperm count (×106/ejaculate) during the combined treatment phaseCC BY · PubMed Central
Fig. 3 a Mean (±SD) percentage of progressively motile sperm during the combined treatment phase; b Mean (±SD) percentage of normal morphology sperm during the combined treatment phase
Fig. 3 a Mean (±SD) percentage of progressively motile sperm during the combined treatment phase; b Mean (±SD) percentage of normal morphology sperm during the combined treatment phaseCC BY · PubMed Central
Fig. 4 a–f Mean (±SD) hormone levels from pretreatment baseline to Week 52 of the combined treatment phase
Fig. 4 a–f Mean (±SD) hormone levels from pretreatment baseline to Week 52 of the combined treatment phaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 2

  1. Rohayem J, Zitzmann M, Nieschlag E. Congenital hypogondotropic hypogonadism and Kallmann’s syndrome. Reference Module in Biomedical Sciences. Elsevier 12-Dec-15; doi: 10.1016/B978-0-12-801238–3.98874–3 . · DOI
  2. WHO Laboratory Manual for the Examination and Processing of Human Sperm, 5th edition. Geneva: World Health Organisation; 2010.

Cited by

See all 45

Metadata

Authors
Nieschlag, E., Bouloux, P.-M. G., Stegmann, B. J., Shankar, R. R., Guan, Y., Tzontcheva, A., McCrary Sisk, C., & Behre, H. M.
Affiliations
  • University Hospital Münster (DE)
  • The Royal Free Hospital (GB)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • University Hospital in Halle (DE)
Corresponding author
Nieschlag, Eberhard
Venue
Reproductive Biology and Endocrinology
Published
2017-03-07
Volume
15
Issue
1
Pages
17-17
ISSN
1477-7827 (ISSN-L)
OpenAlex
W2593671636
Cited by
45
References
16
Citations by year
2026: 4 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 3 · 2017: 1
FWCI
4.44
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Reproductive Biology and Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Merck
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
corifollitropin alfa, hypogonadotropic hypogonadism, azoospermia, human chorionic gonadotropin, spermatogenesis, testicular volume, androgen deficiency, male infertility, anti-drug antibodies, treatment efficacy and safety, combined hormone therapy, spermatogenesis induction
MeSH terms
Adult, Drug Administration Schedule, Chorionic Gonadotropin, Humans, Hypogonadism, Male, Middle Aged, Organ Size, Spermatogenesis, Testis, Treatment Outcome, Follicle Stimulating Hormone, Human, Azoospermia, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. https://app.cochat.ai/papers/10.1186/s12958-017-0232-y
The paper
Nieschlag, E., Bouloux, P.-M. G., Stegmann, B. J., Shankar, R. R., Guan, Y., Tzontcheva, A., McCrary Sisk, C., & Behre, H. M. (2017). An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. Reproductive Biology and Endocrinology. https://doi.org/10.1186/s12958-017-0232-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.